Pilot study demonstrates clinical improvement from gambir extract gel in mild-to-moderate acne vulgaris, highlighting its potential as a topical plant-based therapy.
Acne vulgaris (AV) significantly affects quality of life and is often treated with topical therapies. Gambir, a phytopharmaceutical with catechin as its primary compound, offers an alternative solution for mild-to-moderate AV, acting as an anti-inflammatory, antimicrobial, and astringent. This study investigates the efficacy of 1% gambir extract gel in treating AV, contributing to the exploration of novel dermatological interventions. The pilot study at the General Hospital of Mohammad Hoesin, Palembang, assessed the impact of a 1% gambir extract gel on individuals with AV. A total of 22 subjects, including those with sensitive skin, were enrolled in the study. Data analysis involved comparing the severity of AV before and after treatment with the gel, as well as skin analysis and dermatological quality of life index before and after treatment. Results indicated significant clinical improvement (p < 0.001) in 77.2% of subjects by week 8. Notably, 83.3% of moderate AV cases improved to mild, and 70% of mild AV cases showed improvement. Erythema and sebum levels decreased, and life quality, assessed by the Dermatology Life Quality Index (DLQI), improved in 72.7% of subjects (p < 0.001) by week 8. These findings suggest promising outcomes with 1% gambir extract gel and encourage further research for validation and refinement, emphasizing its potential in managing mild–moderate AV.
No takes yet. Share an insight, caveat, or question.
Kurniawati et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: